Real-time Estimate Cboe BZX 03:47:37 2024-04-22 pm EDT 5-day change 1st Jan Change
41.3 USD +3.24% Intraday chart for Qiagen N.V. +4.01% -7.85%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations MT
QIAGEN NV : Deutsche Bank reiterates its Buy rating ZD
Qiagen N.V. Strengthens Its Portfolio for Cancer Research, Showcases Latest Product Launches At AACR Annual Meeting 2024 CI
Mybio Are the New Exclusive Partner for Qiagen in Ireland & Northern Ireland CI
QIAGEN Introduces QIAstat-Dx Analyzer 2.0 with Remote Test Results Access, Enhancing Collaboration Across Healthcare System CI
Qiagen Teams Up With Physicians Association for Tuberculosis Screening Program MT
Transcript : Qiagen N.V. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM
QIAGEN NV : UBS reaffirms its Neutral rating ZD
Morgan Stanley Upgrades Qiagen to Overweight From Equalweight, Adjusts Price Target to $49.48 From $51 MT
QIAGEN NV : Berenberg reiterates its Buy rating ZD
QIAGEN NV : Deutsche Bank remains its Buy rating ZD
Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep CI
QIAGEN NV : JP Morgan reiterates its Buy rating ZD
QIAGEN NV : UBS reiterates its Neutral rating ZD
QIAGEN : In line Q4; routine business prospects remain intact Alphavalue
Dpa-AFX Overview: COMPANIES from 07.02.2024 - 15:15 DP
Sector Update: Health Care Stocks Mixed Premarket Wednesday MT
Transcript : Qiagen N.V., Q4 2023 Earnings Call, Feb 07, 2024
QIAGEN NV : Gets a Neutral rating from UBS ZD
QIAGEN NV : Berenberg reaffirms its Buy rating ZD
QIAGEN NV : DZ Bank gives a Buy rating ZD
QIAGEN NV : Deutsche Bank reiterates its Buy rating ZD
Qiagen Q4 Adjusted Earnings, Sales Rise; 2024 Outlook Issued, Shares Slump MT
Qiagen N.V. Provides Earnings Guidance for Year 2024 CI
Qiagen N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chart Qiagen N.V.
More charts
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
40 USD
Average target price
50.74 USD
Spread / Average Target
+26.85%
Consensus
  1. Stock Market
  2. Equities
  3. QGEN Stock
  4. News Qiagen N.V.
  5. Qiagen: In line Q4; routine business prospects remain intact